A61K 39/001189
Prame
Official title: {prame}
A61K39/001189 (Prame) appears on 83 US grants and 198 published applications in this corpus.
Search patents in A61K- Granted patents
- 83
- Published applications
- 198
- Assignees
- 57
- Inventors
- 244
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 3 |
| 2006 | 0 | 6 |
| 2007 | 0 | 3 |
| 2008 | 1 | 6 |
| 2009 | 0 | 0 |
| 2010 | 0 | 3 |
| 2011 | 3 | 5 |
| 2012 | 0 | 8 |
| 2013 | 1 | 2 |
| 2014 | 0 | 4 |
| 2015 | 1 | 7 |
| 2016 | 4 | 19 |
| 2017 | 1 | 6 |
| 2018 | 4 | 8 |
| 2019 | 5 | 7 |
| 2020 | 7 | 8 |
| 2021 | 5 | 16 |
| 2022 | 24 | 31 |
| 2023 | 6 | 38 |
| 2024 | 5 | 8 |
| 2025 | 11 | 5 |
| 2026 | 3 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fusion peptide vaccines15 Sep 2026US 12,734,225 B2Treos Bio Limited
- Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof26 May 2026US 12,636,344 B2Regeneron Pharmaceuticals, Inc.
- Antigen binding proteins specifically binding PRAME10 Mar 2026US 12,570,760 B2Immatics Biotechnologies GmbH
- Tumor antigens for determining cancer therapy9 Sep 2025US 12,410,221 B2BioNTech SE
- Compositions and methods for delivery of biomacromolecule agents10 Jun 2025US 12,324,843 B2The Regents of the University of Michigan
- Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof10 Sep 2026US 2026/0263558 A1Regeneron Pharmaceuticals, Inc.
- Uveal melanoma vaccine26 Feb 2026US 2026/0053905 A1University of Virginia Patent Foundation
- Tumor Antigens for Determining Cancer Therapy19 Feb 2026US 2026/0049112 A1BioNTech SE
- Therapeutic rna for lung cancer25 Sep 2025US 2025/0295746 A1
- Compositions and methods for delivery of biomacromolecule agents25 Sep 2025US 2025/0295805 A1The Regents of the University of Michigan
Most cited
By later US patents
- Vaccines102US 6,544,518 B1SmithKline Beecham Biologicals s.a. · 2003
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Method of epitope discovery45US 6,861,234 B1MannKind Corporation · 2005
- Compostition and therapeutic anti-tumour vaccine39US 9,364,504 B2Erytech Pharma · 2016